The Details

Take your laboratory to the next level of productivity with Capture-R^® Ready-Screen^®, a proven IgG specific solid phase technology for antibody screening.

High Accuracy.

• Detect clinically significant antibodies with IgG specific technology - compares to enzyme methods without the added work¹
• Provides high sensitivity for clinically significant antibodies, without the noise of IgM
• Reports describe the use of Werfen products to help mitigate interference with monoclonal antibody therapies^{2, 3}

Easy to Use.

• Save time with ready to use reagents
• No liquid screening cells to manage because antigens are precoated on the microwells
• Less hands-on time with no precision pipetting required
• Simplify training with the same methodology and procedures for all assays

Versatility and Flexibility for Labs of All Sizes.

• A wash step allows for the use of slightly lipemic or hemolyzed samples
• Run a single sample or a full batch
• Manual, semi-automated and fully automated scalable solutions
• Multiple options in automated red blood cell antibody detection

​

Trust Capture for Reliability.

Capture-R Ready-Screen is the method of choice for screening over 90% of the North American blood supply and has been utilised in renowned blood donor centres globally for nearly 40 years.

​​​​​Consistent and Accurate Manufacturing.

Werfen has a rich supply of donors. Our database of over 10,000 typed donors is utilised to create the best antigen profile on every lot.

Our donors are phenotyped by two separate laboratories using unique reagents.

1 Funato, Y. (2018, March). Scientific Study on Comparison of Column with Enzyme and Capture without Enzyme. Toyonaka, Japan; Toyonaka Hp.

2 Howard-Menk C, Crane JE, Doshi L, Papari M. HU5F9-G4 Monoclonal Anti-CD47 Therapy: A First Experience with Interference in Antibody Identification. Transfusion 2018; 58 [S2]:177A.​​​​​​​​​​​​​​​

3 De Vooght KMK, Lozano M, Bueno JL, et al. Vox Sanguinis International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy: summary. Vox Sanguinis 2018; 113:492-498.

Product offerings may differ by region, please check with your local Werfen representative for regulatory status in your area.